Antimutagenic and antioxidative effects of polysaccharides isolated from the water extract of Ganoderma lucidum

Lee, Hyeong-Ryeol; Lim, Heung-Bin

doi:10.7324/japs.2019.90401

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our results, it can reasonably assume that b-glucans polysaccharide helps to prevent or decrease the growth of cancer cells and maybe prevent the mutations as well. Our results (Table 4) are consistent with [48] who found that Ganoderma lucidum polysaccharide (GLP) isolated from G. lucidum which is the major compound of b-glucans can inhibit the mutations, also it is in complete agreement with [69] that b-glucans extracted from oyster mushrooms displays anti-neoplastic activity against MCF-7 line [70]. The reason for the anticancer properties is probably because of the activity of b-glucans polysaccharide, particularly in b-1,3 bound sites [71,72].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Molecular characterization of wild Pleurotus ostreatus (MW457626) and evaluation of β-glucans polysaccharide activities

Hasan¹,

Abdulhadi²

2022

Karbala International Journal of Modern Science

View full text Add to dashboard Cite

Pleurotus ostreatus is a common cultivated edible mushroom worldwide. The fruiting bodies of P. ostreatus is a rich source of a β-glucans polysaccharide. The current study aimed to investigate the effectiveness of β-glucans as a natural polysaccharide produced by P. ostreatus as an antioxidant, antimicrobial, and anticancer. The molecular identification of P. ostreatus isolate was confirmed by Internal Transcribed Spacer (ITS) sequence. The sequence alignment and phylogenetic evolutionary relationship of studied ITS sequence were performed against some deposited sequences in GenBank. The analysis of high-performance liquid chromatography (HPLC) as well as the result of fourier transform infrared spectroscopy (FTIR) has confirmed the presence of β-glucans polysaccharide in the tested samples. The percentage of antioxidant activity of β-glucans showed a gradual increase from 8.

show abstract

Section: Discussionsupporting

confidence: 92%

“…The purified b-glucans isolated from P. ostreatus were subjected to antioxidant measurement using 2,2-diphenyl-1-picrylhydrazyl or DPPH radical scavenging technique [48]. The stock concentration of 400 mg/ml was made by dissolving 0.04 g of DPPH into 100 ml of methanol.…”

Section: B-glucans Activities 241 Measurement Of Antioxidant Efficacy...mentioning

confidence: 99%

Molecular characterization of wild Pleurotus ostreatus (MW457626) and evaluation of β-glucans polysaccharide activities

Hasan¹,

Abdulhadi²

2022

Karbala International Journal of Modern Science

View full text Add to dashboard Cite

show abstract

“…The biopharmaceutical sector generates employment opportunities and stimulates economic activities in numerous countries worldwide (DiMasi et al, 2003). Additionally, the industry's investment in research and development (R&D) has facilitated the emergence of innovative technologies, including cutting-edge drug R&D technologies and digital health solutions (Lee & Lim, 2019).…”

Section: Research Backgroundmentioning

confidence: 99%

Managing University-Industry Collaborative Innovation in the Pharmaceutical Industry

View full text Add to dashboard Cite

The significance of university-industry collaboration becomes even more pronounced within the pharmaceutical R&D context. Such collaborations provide a platform to address potential challenges by offering access to cutting-edge research, specialized facilities, and expertise. Collaborative models, such as multi-university partnerships and university-industry contract research, have emerged as viable methods to support innovation in the pharmaceutical industry. Such collaborations have facilitated universities in accessing invaluable resources from their industrial counterparts, while industries have benefited from enhanced technological capabilities and foundational scientific knowledge. This symbiotic relationship not only benefits the primary stakeholders but also has broader societal implications, as it accelerates the transfer of scientific results to the market. This research adopts a broad definition of pharmaceutical university-industry R&D collaboration. The primary objective is to gain insights to answer the overarching question: How to manage innovation in pharmaceutical university-industry R&D practices? To answer this, the present research employs both quantitative (Chapters 2 and 3) and qualitative (Chapters 4 and 5) methodologies, with a multi-level analysis encompassing landscape- (Chapter 2), collaboration- (Chapter 3), university- (Chapter 4), and company (Chapter 5) perspectives. Based on the landscape perspective, Chapter 2 uses a bibliometric approach to analyze historical and emerging topics in the pharmaceutical UIC R&D context. The study identifies a rise in related publications, emphasizing the research’s importance. The comprehensive review categorizes publications into three levels that are industrial and organizational innovation strategy, -structure, and -culture. The chapter advocates for broader engagement by academic and commercial entities, emphasizing the potential of R&D alliances in the pharmaceutical industry, where university-industry collaborations are particularly promising. Chapter 3, using Neglected Tropical Diseases as the focal point, delves into whether the type of PPPs influences the initiation and duration of NTD-related clinical trials. The research identifies various collaborative types, among which NGO- and public sector-led collaborations are the major subtypes. Key determinants shaping these collaborations encompass scientific, logistical, political, and financial aspects. The chapter emphasizes the pivotal role companies play in combating NTDs, either independently or within public-private partnerships. The identified characteristics and determinants provide suggestions for practitioners to further optimize R&D strategies. Chapter 4 delves into the micro-foundations of dynamic capabilities within the university technology transfer process, drawing from empirical cases of the Industry Alliance Office and the Demonstrator Lab. For sensing capabilities, this chapter underscores the importance of timely identification of opportunities through internal competencies and external partnerships. On the seizing front, the research highlights the critical role of universities in aligning with industrial entities to maximize detected opportunities, emphasizing resource co-allocation and collaborative business models. Reconfiguring capabilities are important for universities to position themselves as central orchestrators within the broader of university-industry ecosystem. It is also important for partnering companies and academic entrepreneurs to employ dynamic capabilities with the aim of academic entrepreneurship. Chapter 5 delves into the micro-foundations of dynamic capabilities essential for academic entrepreneurship within the university-industry ecosystem. It emphasizes that sensing capabilities empower them to strategically allocate resources and address potential challenges. The chapter also underscores the significance of seizing capabilities in facilitating knowledge integration and partnership management. To ensure sustained innovation, it is important for high-tech enterprises to develop reconfiguring capabilities. To further research pharmaceutical UIC R&D innovation management, Chapter 6 then puts forward various recommendations to different stakeholders including universities, research institutes, startup companies, and regulatory agencies. Chapter 6 also adds some of the limitations of Chapters 2-5, based on which the present research hopes to provide some suggestions for future research.

show abstract

Current Trends and Future Perspectives of Antimutagenic Agents

AbdelHakem¹,

Abdelhafez²

2021

Genotoxicity and Mutagenicity - Mechanisms and Test Methods

View full text Add to dashboard Cite

Mutation is the process leading to heritable changes in DNA caused mainly by internal and external factors. Recently, studies on mutagenic agents have been increased due to increasing in mutation-related disease. The antimutagenic effect is desired to prevent mutation on genes or to inactivate the mutagenic agent. It seems that the interest in antimutagenic substances displaying multiple mechanisms of action will be an important trend in the research and development of new antimutagenic compounds in the near future. Therefore, this chapter displays various possible mechanisms of action for antimutagenic agent and introduces different types of antimutagens, natural and synthetic, that are considered very important.

show abstract

Antimutagenic and antioxidative effects of polysaccharides isolated from the water extract of Ganoderma lucidum

Cited by 3 publications

References 25 publications

Molecular characterization of wild Pleurotus ostreatus (MW457626) and evaluation of β-glucans polysaccharide activities

Molecular characterization of wild Pleurotus ostreatus (MW457626) and evaluation of β-glucans polysaccharide activities

Managing University-Industry Collaborative Innovation in the Pharmaceutical Industry

Current Trends and Future Perspectives of Antimutagenic Agents

Contact Info

Product

Resources

About